Bone Marrow Mesenchymal Stem Cells Exert Protective Effects After Ischemic Stroke Through Upregulation of Glutathione

• Published in: Stem cell reviews and reports Vol. 18; no. 2; p. 585
• Main Authors: Lan, Xiao-Yan, Sun, Zheng-Wu, Xu, Gui-Lian, Chu, Cheng-Yan, Qin, Hua-Min, Li, Shen, Geng, Xin, Gao, Peng, Boltze, Johannes
• Format: Journal Article
• Language: English
• Published: United States 01-02-2022
• Subjects: Animals; Bone Marrow Cells - metabolism; Glutathione - metabolism; Glutathione - pharmacology; Glutathione - therapeutic use; Humans; Infarction, Middle Cerebral Artery - metabolism; Ischemic Stroke; Mesenchymal Stem Cells - metabolism; Pyrrolidonecarboxylic Acid - metabolism; Pyrrolidonecarboxylic Acid - pharmacology; Pyrrolidonecarboxylic Acid - therapeutic use; Rats; Stroke - metabolism; Stroke - therapy; Up-Regulation; Metabolomics; 5-oxoproline; Ischemic stroke; Bone marrow mesenchymal stem cells; Oxidative Stress; Glutathione
• DOI: 10.1007/s12015-021-10178-y
• EISSN: 2629-3277

Bone marrow mesenchymal stem cells (BMSCs) have been shown to promote stroke recovery, however, the underlying mechanisms are not well understood. In this study naïve rats were intravenously injected with syngeneic BMSCs to screen for potential differences in brain metabolite spectrum versus vehicle-treated controls by capillary electrophoresis-mass spectrometry. A total of 65 metabolites were significantly changed after BMSC treatment. Among them, 5-oxoproline, an intermediate in the biosynthesis of the endogenous glutathione (GSH), was increased. To confirm the obtained results and investigate the metabolic pathways, BMSCs were injected into rats 24 h after middle cerebral artery occlusion (MCAO). Rats receiving vehicle solution and sham-operated animals served as controls. High performance liquid chromatography, reverse transcription-quantitative polymerase chain reaction, and Western blotting revealed that intravenous BMSC application increased the levels of 5-oxoproline and GSH in MCAO rats, as well as the expression of key enzymes involved in GSH synthesis including, gamma-glutamylcyclotransferase and gamma-glutamylcysteine ligase. Subsequent clinical investigation confirmed that acute ischemic stroke patients had higher plasma 5-oxoproline and GSH levels than age- and sex-matched non-stroke controls. The optimal cutoff value for 5-oxoproline diagnosing acute ischemic stroke (≤ 7d) was 3.127 µg/mL (sensitivity, 63.4 %; specificity, 81.2 %) determined by receiver characteristic operator curve. The area under the curve was 0.782 (95 % confidence interval: 0.718-0.845). Our findings indicate that BMSCs play a protective role in ischemic stroke through upregulation of GSH and 5-oxoproline is a potential biomarker for acute ischemic stroke. Ischemic stroke causes oxidative stress and induction of endogenous, glutathione-dependent anti-oxidative mechanisms. 5-oxoproline, an important metabolite in glutathione biosynthesis, could serve as a biomarker of acute ischemic stroke. Moreover, intravenous bone marrow mesenchymal stem cell (BMSC) treatment after experimental stroke upregulates the expression of key enzymes involved in glutathione synthesis, which results in better antioxidative defense and improved stroke outcome.